Search

Your search keyword '"Chow, Pierce K."' showing total 595 results

Search Constraints

Start Over You searched for: Author "Chow, Pierce K." Remove constraint Author: "Chow, Pierce K."
595 results on '"Chow, Pierce K."'

Search Results

1. APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024

3. Multi-region sampling with paired sample sequencing analyses reveals sub-groups of patients with novel patient-specific dysregulation in Hepatocellular Carcinoma

5. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

6. Pan-cancer pervasive upregulation of 3′ UTR splicing drives tumourigenesis

8. Trajectory of immune evasion and cancer progression in hepatocellular carcinoma

10. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial

17. Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma

18. Author Correction: Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma

22. Laparoscopic Liver Resection Difficulty Score—a Validation Study

25. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

32. The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres

33. Additional file 6 of Multi-region sampling with paired sample sequencing analyses reveals sub-groups of patients with novel patient-specific dysregulation in Hepatocellular Carcinoma

34. Additional file 10 of Multi-region sampling with paired sample sequencing analyses reveals sub-groups of patients with novel patient-specific dysregulation in Hepatocellular Carcinoma

35. Additional file 8 of Multi-region sampling with paired sample sequencing analyses reveals sub-groups of patients with novel patient-specific dysregulation in Hepatocellular Carcinoma

36. Additional file 3 of Multi-region sampling with paired sample sequencing analyses reveals sub-groups of patients with novel patient-specific dysregulation in Hepatocellular Carcinoma

38. Extending surgical resection for hepatocellular carcinoma beyond Barcelona Clinic for Liver Cancer (BCLC) stage A: A novel application of the modified BCLC staging system.

40. Intraoperative blood transfusion does not impact overall and recurrence‐free survival after curative hepatectomy for hepatocellular carcinoma: A propensity‐score‐matched and inverse probability of treatment‐weighted study

42. Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in an International Cohort

43. CD38 marks the exhausted CD8+ tissue-resident memory T cells in hepatocellular carcinoma.

47. Genome instability is associated with ethnic differences between Asians and Europeans in hepatocellular carcinoma

49. Hypoxia‐driven immunosuppression by Treg and type‐2 conventional dendritic cells in HCC

50. Additional file 1 of Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors

Catalog

Books, media, physical & digital resources